Alendronate
Top in endocrinology: Romosozumab vs. alendronate, health effects of shift work
Data showed that 1 year of romosozumab followed by a year of alendronate was associated with larger gains in bone mineral density at the lumbar spine than 2 years of alendronate alone in postmenopausal women with osteoporosis.
Greater lumbar spine BMD, bone strength gains with romosozumab for postmenopausal women
Postmenopausal women with osteoporosis receiving romosozumab for 12 months had larger improvements in bone mineral density and bone strength at the lumbar spine compared with those receiving alendronate alone, according to study data.
Denosumab increasingly prescribed in osteoporosis treatment
The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now the second most used medication after alendronate, according to data presented at the ENDO annual meeting.
Denosumab superior to alendronate in raising spinal BMD in long-term glucocorticoid users
Among patients using long-term glucocorticoids, denosumab is superior to alendronate in increasing bone mineral density in the spine after 1 year, according to a speaker at ACR Convergence 2020.
Treatment sequence influences romosozumab effectiveness in osteoporosis
Women with osteoporosis who received romosozumab experienced the greatest gains in bone formation when the drug was administered before antiresorptive therapy, according to a speaker.
Romosozumab reduces vertebral fracture risk in postmenopausal osteoporosis
Women with postmenopausal osteoporosis who received the monoclonal antibody romosozumab were less likely to sustain a vertebral fracture during 12 months of treatment compared with women who received placebo or alendronate, study data show.
Great Debate tackles first-line anabolic therapy for glucocorticoid-induced osteoporosis
ATLANTA — The 2019 iteration of the ACR/ARP Great Debate tackled the issue of whether anabolic therapies are appropriate for patients with glucocorticoid-induced osteoporosis.
Bone strength, BMD increase more substantially with romosozumab vs. alendronate
Among a cohort of postmenopausal women randomly assigned to romosozumab or alendronate, larger improvements in bone mineral density and bone strength in the lumbar spine were observed for those taking romosozumab, according to findings presented at the American Society of Bone and Mineral Research annual meeting.
BMD gains can be maintained when switching from denosumab to alendronate
Postmenopausal women who took denosumab for a year did experienced no significant decrease in bone mineral density after switching to alendronate, according to findings presented at the American Society of Bone and Mineral Research annual meeting.